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Traditional and Nontraditional Glycemic Markers and Risk of Peripheral Artery 
Disease: the Atherosclerosis Risk in Communities (ARIC) Study 
 
Introduction: Traditional glycemic markers, fasting glucose and hemoglobin A1c 
(HbA1c), predict incident peripheral artery disease (PAD). However, it is unknown 
whether nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-
anhydroglucitol (1,5-AG), have additional predictive value for PAD. Also, whether these 
glycemic markers demonstrate different associations with overall PAD and its severe 
form, critical limb ischemia (CLI), is yet to be evaluated.  
Methods: We quantified the associations of these five glycemic markers with incident 
PAD (defined as hospitalizations with PAD diagnosis [ICD-9: 440.2-440.4] or leg 
revascularization [e.g., 38.18]) in 10,310 ARIC participants free of a history of PAD at 
baseline (1990-92) using Cox proportional hazards models. Of those with PAD, cases 
with an ICD code of ulcer, gangrene, or leg amputation were considered CLI. Participants 
were categorized into five groups according to the status of diabetes diagnosis and 
clinical cut-points of fasting glucose (<7.2, ≥7.2 mmol/L in diagnosed diabetes and <5.6, 
5.6-6.9, ≥7.0 mmol/L in no diagnosed diabetes) and HbA1c (<7, ≥7% in diagnosed 
diabetes and <5.7, 5.7-6.4, and ≥6.5% in no diagnosed diabetes). The other glycemic 
markers were categorized according to percentiles corresponding to the HbA1c cut-
points. 
Results: Over a median follow-up of 18.4 years, there were 365 cases of PAD (126 were 
CLI). Both diagnosed diabetes and higher levels of HbA1c significantly contributed to 
increased risk of incident PAD (e.g., compared to no diagnosed diabetes with HbA1c 
<5.7%, the adjusted hazard ratio [HR] was 8.74 [95% confidence interval, 6.50-11.75] in 
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diagnosed diabetes with HbA1c ≥7% and 3.25 [2.14-4.93] in no diagnosed diabetes with 
HbA1c ≥6.5%). Fasting glucose showed weaker associations than HbA1c. The three 
nontraditional glycemic markers demonstrated similar risk gradient as HbA1c (e.g., 
adjusted HR ranged from 5.7-6.9 in diagnosed diabetes with higher levels vs. no 
diagnosed diabetes with lowest levels [lower and highest levels for 1,5-AG, 
respectively]), but once adjusting for HbA1c, their risk gradient was substantially 
attenuated. All glycemic markers, particularly HbA1c and the nontraditional glycemic 
markers, consistently demonstrated stronger associations with CLI (HRs ranging 12-21 in 
diagnosed diabetes with higher levels) than overall PAD (p for difference in HRs between 
CLI and PAD without CLI <0.001 in all glycemic markers).  
Conclusions: Nontraditional glycemic markers provided similar predictive value as 
HbA1c for incident PAD but might not provide much additional information beyond 
HbA1c. Our results also support the importance of glucose metabolism in the progression 
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Peripheral artery disease (PAD) is a condition characterized by atherosclerotic 
occlusive disease of the lower extremities [1], affecting approximately 8 to 12 million 
Americans [2, 3]. Approximately 1 of 5 patients with PAD die in 5 years [4, 5]. Critical 
limb ischemia (CLI) is a severe form of PAD [6], and 10% to 40% of patients with CLI 
require major amputation within 6 months after its diagnosis [2, 7]. Although amputation 
rates have recently decreased among patients with PAD over years [8], ~150,000 legs are 
still amputated due to PAD annually in the U.S. [9].  
Although traditional atherosclerotic risk factors increase the risk of PAD, diabetes is 
known to be particularly strongly associated with PAD [10-12], with a relative risk of 3- 
to 4-fold compared to non-diabetes [13, 14]. Therefore, the American Diabetes 
Association (ADA) recommends annual foot care for patients with diabetes [15]. 
However, the adherence to this recommendation is reported to be ~30% [16, 17], and 
thus biomarkers that can classify the risk of PAD among diabetic patients may be helpful 
for targeted foot care.  
In this context, traditional glycemic markers, fasting glucose and hemoglobin A1c 
(HbA1c), would be promising since they are routinely measured in patients with diabetes 
and predict PAD [18-22]. Although no studies have compared these two glycemic 
markers for PAD risk, previous studies have demonstrated the superiority of HbA1c to 
fasting glucose for predicting other cardiovascular outcomes and mortality [23-25]. 
However, HbA1c has a few caveats such as not reflecting recent changes in glucose 
levels and being influenced by red blood cell turnover (e.g., due to anemia) [26-30]. Also, 
it requires whole blood specimen to measure, often precluding its retrospective 
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measurement in a research setting, where only serum and/or plasma samples are typically 
stored.  
Some nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-
anhydroglucitol (1,5-AG), may overcome these caveats of HbA1c, by reflecting glucose 
levels in the last few weeks, not being affected by red blood cell turn over, and being 
measurable in serum/plasma samples [31-35]. Recently, these nontraditional glycemic 
markers have been shown to predict coronary heart disease (CHD) and stroke similarly as 
HbA1c or provide additional predictive value beyond HbA1c [36, 37]. However, their 
associations with PAD risk have not been quantified. 
Therefore, we comprehensively investigated the associations of traditional (fasting 
glucose and HbA1c) and nontraditional glycemic markers (fructosamine, glycated 
albumin, and 1,5-AG) with incident PAD in a community-based cohort, the 
Atherosclerosis Risk in Communities (ARIC) Study. We also explored whether these 





The ARIC Study enrolled 15,792 participants aged 45-64 years from four U.S. 
communities. The first clinic examinations (visit 1) took place from 1987 to 1989, with 
three short-term follow-up visits (visits 2-4) approximately every 3 years [38]. A total of 
14,348 participants attended visit 2, which was the baseline of this study, given the data 
availability of the glycemic markers of interest. Of those participants, we excluded all 
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persons whose race/ethnicity was recorded as other than white or black (N = 42); who 
had missing variables of interest (N = 3,186); who were fasting <8 h (N = 347); or who 
had prevalent PAD at baseline (N = 463), leaving final sample of 10,310. 
 
Measurement of Glycemic Markers 
Serum glucose was measured using the hexokinase method. HbA1c was measured 
in whole blood samples using high-performance liquid chromatography with instruments 
standardized to the Diabetes Control and Complications Trial assay (Tosoh A1c 2.2. Plus 
Glycohemoglobin and Tosoh G7 analyzers) [39]. Fructosamine (Roche Diagnostics Corp, 
Indianapolis, IN, USA), glycated albumin (Asashi Kasei Lucica GA-L, Tokyo, Japan), 
and 1,5-AG (GlycoMark, Winston-Salem, NC) were measured in 2012–2013 in stored 
serum samples from visit 2 (1990–1992) using a Roche Modular P800 system [36, 40]. 
Previous studies have shown these analytes to be reliable in long-term stored samples 
[41-46].  
 
Other Variables of Interest at Baseline 
Age, gender, race, educational level, alcohol use, and smoking status were self-
reported. Body mass index (BMI) was calculated as body weight (in kilograms) over 
height (in meters) squared. Education was categorized as advanced (completed college or 
more), intermediate (high school to less than college), and no or basic (less than high 
school). Systolic blood pressure (SBP) was measured three times in the sitting position 
after 5 minutes of rest using a random-zero sphygmomanometer, and the average of the 
second and third readings was recorded. Total cholesterol and high-density lipoprotein 
 4 
(HDL) cholesterol were determined using enzymatic methods. Glomerular filtration rate 
was estimated using the Chronic Kidney Disease Epidemiology Collaboration creatinine 
equation [47]. Medication use was verified by reviewing medication containers that 
participants brought to the visit. Diagnosed diabetes was defined as self-reported 
physician diagnosis of diabetes or current use of glucose lowering medications. History 
of CHD was defined by self-reported history of physician-diagnosed myocardial 
infarction, prior coronary reperfusion procedure, electrocardiogram evidence of 
myocardial infarction at visit 1, or adjudicated CHD events between visit 1 and visit 2 
[48]. History of stroke was defined as a self-reported history of stroke at visit 1 or 
adjudicated stroke events between visit 1 and visit 2. 
 
Incident Peripheral Artery Disease 
Based on previous literature [21,22], incident PAD was defined as hospitalizations 
with the following International Classification of Diseases (ICD) codes: atherosclerosis 
of native arteries of the extremities, unspecified (440.20); atherosclerosis of native 
arteries of the extremities with intermittent claudication (440.21); atherosclerosis of 
native arteries of the extremities with rest pain (440.22); atherosclerosis of native arteries 
of the extremities with ulceration (440.23); atherosclerosis of native arteries of the 
extremities with gangrene (440.24); other atherosclerosis of native arteries of the 
extremities (440.29); atherosclerosis of bypass graft of the extremities (440.3); 
atherosclerosis of other specified arteries (440.8); leg artery revascularization (38.18, 
39.25, 39.29, 39.50). Of these, cases based on 440.22, 440.23, and 440.24 as well as PAD 
cases with coexisting leg amputation (84.1x), lower extremity ulcer (707.1x), and 
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gangrene (785.4) were considered CLI. Participants were followed until incident PAD, 
date of death, date of the last contact, or December 31, 2012, whichever came first.  
 
Statistical Analyses 
We first categorized participants into five groups according to the status of diagnosed 
diabetes and levels of traditional glycemic markers. We used clinical cut-points 
recommended by the ADA to categorize fasting glucose and HbA1c [49]. Specifically, 
fasting glucose levels were categorized into <5.6, 5.6-6.9, and ≥7 mmol/L in no 
diagnosed diabetes and <7.2, ≥7.2 mmol/L in diagnosed diabetes. Similarly, HbA1c were 
categorized into <5.7, 5.7-6.4, and ≥6.5% in no diagnosed diabetes and <7, ≥7% in 
diagnosed diabetes. We subsequently categorized participants into five groups by the 
status of diagnosed diabetes and percentiles of for nontraditional glycemic markers 
corresponding to HbA1c cut-points since their clinical cut-points are not established. In 
persons with no diagnosed diabetes, HbA1c values of 5.7% and 6.5% corresponded to the 
77th percentile and the 96th percentile, respectively. In persons with diagnosed diabetes, 
HbA1c of 7% was equivalent to the 32nd percentile. The cut-points for 1,5-AG were 
inversed (e.g., 23rd percentile instead of 77th percentile) because its lower values 
indicate hyperglycemia [50]. 
Baseline characteristics of the study population were compared between participants 
with and without incident PAD during follow-up. We used Poisson regression models 
with linear splines to evaluate the continuous association between the glycemic markers 
and incidence rate of PAD with the adjustment of age, sex and race. Cox proportional 
hazards models were used to quantify the independent associations between categories of 
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glycemic markers and incident PAD beyond potential confounders. We constructed three 
models for the adjustment of covariates. Model 1 was adjusted for key demographic and 
clinical factors, age (years), race, sex, education level, BMI, total cholesterol, HDL 
cholesterol, drinking status (current, former, never), smoking status (current, former, 
never), SBP, antihypertensive medication use, lipid lowering medication use, estimated 
glomerular filtration rate (eGFR), history of CHD and stroke. Model 2 was additionally 
adjusted for each of traditional glycemic markers (Model 2a with fasting glucose and 
Model 2b with HbA1c). We primarily used the category with no diagnosed diabetes and 
the lowest level of glycemic markers (highest for 1,5-AG but for convenience we would 
not specify every time in subsequent sections) as a reference but secondarily repeated the 
analysis with the lowest risk group as a reference group in a case of a J-shaped 
association. The proportional hazards assumption was verified using log-log plots. 
Seemingly unrelated regression was used to formally compare the strength of 
associations for each glycemic marker with incident PAD without CLI vs. CLI. 
All statistical analyses were conducted using Stata SE, version 14 (Stata Corp, 




Baseline characteristics of participants by the status of incident PAD during 
follow-up are shown in Table 1. Compared to participants who did not developed PAD, 
those who developed PAD were more likely to be older, male, black race, less educated, 
current smoker, and to have poorer risk factor profile (i.e., higher levels of BMI and SBP, 
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lower eGFR, and higher prevalence of lipid lowering medication use and a history of 
CHD and stroke). Regarding diagnosed diabetic status and glycemic markers, participants 
with incident PAD had ~4-fold higher prevalence of diagnosed diabetes and higher levels 
of all glycemic markers (lower levels of 1,5-AG) than those without incident PAD. These 
patterns were more enhanced in in persons who developed CLI compared with those who 
developed PAD without CLI. More than half of persons who developed CLI had 
diagnosed diabetes at baseline. 
Over a median follow-up of 18.4 years, there were 365 cases of PAD (126 were 
CLI). The overall incidence rate of PAD was 1.9 per 1,000 person-years. The continuous 
associations of five glycemic markers with incidence rate of PAD adjusted for age, sex, 
and race are shown in Figure 1. The incidence rate of PAD increased monotonically along 
with both traditional glycemic markers, although the risk gradient appeared to be steeper 
for HbA1c (e.g., reaching incidence rate of 20 per 1,000 person-years at 99th percentile 
in Figure 1B) than fasting glucose (e.g., incidence rate at 99th percentile <15 per 1,000 
person-years in Figure 1A). The nontraditional glycemic markers were associated with 
increased incidence rate of PAD as well but demonstrated J-shaped associations, although 
less so for 1,5-AG. Their risk gradients appeared to be slightly shallower than HbA1c but 
steeper than fasting glucose (incidence rate at 99th percentile exceeding 15 per 1,000 
person-years in Figures 1C-E).  
After accounting for other potential confounders, both traditional glycemic 
markers showed significant associations with incident PAD (Model 1 in Table 2). Again, 
the associations were stronger for HbA1c than for fasting glucose. Specifically, the 
adjusted hazard ratio (HR) in diagnosed diabetes with HbA1c ≥7% (vs. no diagnosed 
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diabetes with HbA1c <5.7%) was 8.74 (95% confidence interval, 6.50-11.75), whereas 
that in diagnosed diabetes with fasting glucose ≥7.2 mmol/L (vs. no diagnosed diabetes 
with fasting glucose <5.6 mmol/L) was 5.65 (4.11-7.76). In addition, higher HbA1c 
levels, but not fasting glucose levels, were significantly associated with incident PAD 
among no diagnosed diabetes. Persons with prediabetes, indicated by a HbA1c 
concentration of 5.7-6.4%, had ~50% higher risk of PAD compared to those with HbA1c 
<5.7%. The additional adjustment for fasting glucose somewhat attenuated the 
associations for HbA1c (Model 2a in Table 2), but the general patterns remained 
consistent. On the other hand, there was no longer a risk gradient by fasting glucose 
levels among those with diagnosed diabetes after the additional adjustment for HbA1c, 
with both groups showing HR ~2 (Model 2b in Table 2).  
Regardless of traditional glycemic markers, adjusted HRs were generally higher 
for CLI than for PAD, particularly in persons with diagnosed diabetes. For example, the 
adjusted HR for CLI in diagnosed diabetes with HbA1c ≥7% (vs. no diagnosed diabetes 
with HbA1c <5.7%) was 20.78 (12.51-34.50) in Model 1 and 11.55 (5.97-22.36) in 
Model 2a. Based on seemingly unrelated regression, HRs for both traditional glycemic 
markers were significantly greater for CLI than for PAD without CLI (p values <0.001 
for both markers).  
The associations of nontraditional glycemic markers with incident PAD were 
independent of representative cardiovascular risk factors as well (Model 1 in Table 3). 
The adjusted HRs appeared to be slightly smaller than those for HbA1c but greater than 
those for fasting glucose. Specifically, the adjusted HRs in diagnosed diabetes with their 
higher category (vs. no diagnosed diabetes with their lowest category) ranged from 5.7 to 
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6.9. Given a J-shaped association for fructosamine and 1,5-AG, when their lowest risk 
category was used as a reference, the corresponding HRs exceeded 7.5 (Web Table 1). 
Unlike fasting glucose, the adjusted HRs in no diagnosed diabetes with their highest 
category reached statistical significance. The further adjustment for fasting glucose 
attenuated the associations, but the general patterns remained similar (Model 2a in Table 
3). However, when we replaced fasting glucose with HbA1c, the risk gradient within no 
diagnosed diabetes and diagnosed diabetes was not that evident in any of the 
nontraditional glycemic markers.  
Consistently with both traditional glycemic markers, all three nontraditional 
glycemic markers showed greater HRs for CLI than for overall PAD, with HRs adjusted 
for conventional cardiovascular factors ranging from 12 to 17 in diagnosed diabetes with 
higher levels and 3 to 5 in diagnosed diabetes with lower levels (vs. no diagnosed 
diabetes with the lowest levels) (Model 1 in Table 3). Those HRs for CLI were 
significantly greater than those for PAD without CLI in seemingly unrelated regression 
analyses (p for difference <0.001 for all nontraditional glycemic markers).  
 
Discussion 
In this community-based study, both traditional (fasting glucose and HbA1c) and 
nontraditional (fructosamine, glycated albumin, and 1,5-AG) glycemic markers were 
significantly associated with incident PAD, independently of potential confounders. The 
association with incident PAD was particularly strong and robust when persons with and 
without diagnosed diabetes were categorized by HbA1c. Overall, nontraditional glycemic 
markers demonstrated strength of association with PAD in the middle of HbA1c and 
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fasting glucose. Of note, all glycemic markers tested consistently demonstrated stronger 
associations with CLI than overall PAD. 
The independent associations of traditional glycemic markers with PAD were 
consistent with previous reports mainly among diabetic patients [18-22, 51-54], but our 
study extended our knowledge in a few aspects. First, we confirmed these associations in 
the general population (particularly for HbA1c). Specifically, we found persons with 
prediabetes, indicated by a HbA1c concentration 5.7-6.4%, had ~50% higher risk of PAD 
compared to those with HbA1c <5.7%. Second, HbA1c demonstrated stronger 
associations with PAD compared to fasting glucose levels, confirming the pattern 
observed for other cardiovascular outcomes and mortality [23-25]. Third, both traditional 
glycemic markers demonstrated stronger associations with CLI than overall PAD. Fourth, 
while most previous studies were cross-sectional [51-54] or had relatively short duration 
of follow-up (a median of ≤6 years) [19-21], our study explored a long follow-up of over 
22 years.   
To our knowledge, this is the first study reporting the associations of three 
nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-AG, with 
incident PAD, independent of traditional cardiovascular risk factors. Their associations 
with PAD were not as strong as but similar to HbA1c. Once accounting for HbA1c, their 
predictive values for PAD were considerably attenuated. These patterns are generally 
consistent with previous reports from ARIC for other cardiovascular diseases (CHD, 
stroke, and heart failure) [36, 37].  
In our study, we found J-shaped associations of the levels of nontraditional 
glycemic markers (particularly fructosamine in both Figure 1 and Table 3) with incident 
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PAD. Of interest, low levels of fructosamine have been reported to be associated with 
increased risk of mortality [37, 55] and heart failure [37]. Several mechanisms might 
partly explain these associations. Fructosamine values are lower among those with low 
concentration of serum albumin (hypoalbuminemia below 30-35 g/L), as in the case of 
protein-losing enteropathy, nephrotic syndrome, and advanced liver disease like cirrhosis. 
Increased albumin catabolism also leads to low fructosamine levels in hyperthyroidism, 
glucocorticoid administration, and Cushing’s syndrome [56-59]. Therefore, the lowest 
category of fructosamine might include individuals with poor health and low serum 
albumin levels, who were at high risk of PAD. This mechanism of increased albumin 
catabolism also results in low glycated albumin levels, which may be related to a J-
shaped association between glycated albumin and PAD risk. 
Although PAD is often considered as a large artery disease, microvascular disease 
is indicated to play an important factor in the development of CLI, by impairing collateral 
formation and wound healing [60, 61]. Our observation of all five glycemic markers 
consistently demonstrating stronger associations with CLI than overall PAD seems to 
support the involvement of microvascular disease in the pathophysiology of CLI, since 
hyperglycemia is known to be more strongly associated with microvascular disease 
(namely retinopathy, nephropathy, and neuropathy) than macrovascular disease (e.g., 
CHD) in general [62]. In addition, an intensive glycemic control decreases the risk of 
microvascular disease but not necessarily macrovascular disease in patients with diabetes 
[63, 64]. Nonetheless, future studies should explore other parameters of microvascular 
disease (e.g., retinopathy) and their associations with CLI vs. overall PAD. 
Our results have several clinical and research implications. First, HbA1c, the 
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central glycemic marker for glucose control in diabetic patients, would be useful for 
classifying the risk of PAD. Given the low adherence to annual foot care among diabetic 
patients recommended by the ADA, HbA1c may be used to identify diabetic patients who 
would particularly benefit from foot care and monitoring. Second, although an intensive 
glucose control has not consistently shown an evident benefit for reducing overall 
cardiovascular risk, our results suggest that such a tight control may contribute to the 
reduction of CLI. Third, although the three nontraditional glycemic markers did not 
outperform HbA1c for predicting incident PAD, there may be a few scenarios that these 
markers may be useful, since they showed stronger associations than fasting glucose. For 
example, fructosamine and glycated albumin can be measured rapidly, easily, precisely, 
and inexpensively [65]. Therefore, these nontraditional glycemic markers may be used in 
clinical practice or research setting with limited resources (e.g., developing countries 
[66]). In addition, these nontraditional glycemic markers can be assessed with serum and 
plasma samples, while HbA1c requires the whole blood sample. Therefore, when 
research studies or trials have only stored serum or plasma, these nontraditional glycemic 
markers would be reasonable alternatives as useful glycemic markers and potent 
predictors for PAD. 
There are several limitations in our study. First, glycemic markers were based on 
single measurement at baseline. Second, the definition of PAD (and CLI) relied on 
discharge diagnostic codes. Thus, asymptomatic cases and mild cases were unlikely to be 
captured. However, it is important to study severe PAD, since revascularization 
procedures and inpatient care account for majority of medical expenditure related to PAD 
(e.g.,  $3.9 billion for total Medicare paid PAD-related care annually) [67, 68]. Third, we 
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are not able to eliminate the possibility of residual confounding, as is the case in any 
observation studies. Finally, we investigated whites and blacks aged 47-70 years, so the 
results may not be generalizable to other racial or age groups.  
In conclusion, traditional (particularly HbA1c) and nontraditional glycemic 
markers were strongly associated with incident PAD, independently of potential 
confounders. Additional prognostic values of nontraditional glycemic markers beyond 
HbA1c for PAD were not evident. Nonetheless, all five glycemic markers demonstrated 
stronger associations with CLI than overall PAD. These results suggest the usefulness of 
HbA1c and nontraditional glycemic markers to identify persons (particularly with 
diabetes) at high risk of PAD and the importance of hyperglycemia in the progression to 
CLI. 
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Tables and figures 
Table 1. Baseline Characteristics by Categories of PAD during Follow-up (N=10,310) 
  Overall No PAD PAD 
Characteristic 
  
All PAD without CLI CLI 
n 10,310 9,945 365 239 126 
Age, years 57.0 (5.7) 56.9 (5.7) 58.8 (5.5) 58.9 (5.4) 58.5 (5.7) 
Female, % 58.5 59.0 46.0 41.4 54.8 
Black, % 22.7 22.5 27.1 17.2 46.0 
Body mass index, kg/m2 28.0 (5.4) 28.0 (5.4) 29.0 (5.4) 28.2 (4.9) 30.5 (6.0) 
Education level, % 
  
 
       No or basic 20.3 19.9 31.2 26.4 40.5 
     Intermediate  41.9 42.1 38.6 39.3 37.3 
     Advanced  37.7 38.0 30.1 34.3 22.2 
Smoking status, % 
  
 
       Current smoker, % 20.4 19.8 34.8 38.5 27.8 
     Former smoker, % 38.6 38.7 37.5 39.3 34.1 
Drinking status, % 
  
 
       Current drinker, % 56.9 57.0 53.4 61.9 37.3 
     Former drinker, % 20.6 20.4 26.3 23.0 32.5 
Diagnosed diabetes, % 8.3 7.4 31.0 19.2 53.2 
Blood glucose, mmol/L 6.27 (2.21) 6.20 (2.07) 8.16 (4.22) 7.13 (3.22) 10.10 (5.14) 
HbA1c, % 5.75 (1.17) 5.71 (1.10) 6.89 (2.19) 6.27 (1.51) 8.06 (2.74) 
Fructosamine, μmol/L 238.40 (47.96) 237.00 (44.88) 276.58 (92.72) 251.48 (63.67) 324.18 (117.58) 
Glycated albumin, % 13.55 (3.76) 13.44 (3.49) 16.69 (7.53) 14.46 (4.83) 20.90 (9.67) 
1,5-Anhydroglucitol, ug/ml 17.63 (6.61) 17.75 (6.47) 14.54 (9.23) 16.49 (8.34) 10.83 (9.71) 
Systolic blood pressure, mmHg 121.3 (18.5) 121.0 (18.3) 129.4 (21.9) 128.0 (20.9) 132.1 (23.5) 
Total cholesterol, mmol/L 5.43 (1.02) 5.42 (1.01) 5.62 (1.10) 5.58 (1.06) 5.68 (1.18) 
 15 
HDL cholesterol, mmol/L 1.30 (0.44) 1.30 (0.44) 1.10 (0.35) 1.10 (0.36) 1.09 (0.32) 
eGFR, ml/min 96.3 (15.5) 96.5 (15.1) 90.7 (23.1) 90.1 (19.3) 91.9 (29.0) 
Antihypertensive medication, % 36.4 35.5 60.8 57.3 67.5 
Lipid lowering medication, % 7.1 6.9 13.2 13.4 12.7 
History of coronary heart disease, % 6.0 5.4 20.5 23.0 15.9 







Table 2. Adjusted HRs (95% CIs) for peripheral artery disease and critical limb ischemia by categories of fasting glucose and HbA1c (N = 10,310) 
  
Peripheral artery disease  
n=365 
Critical limb ischemia 
n=126 
 
Model 1 Model 2a Model 2b Model 1 Model 2a Model 2b 
Fasting glucose 
      
No diagnosis of diabetes 
      
 <5.6 mmol/L 1 (reference) 
 
1 (reference) 1 (reference) 
 
1 (reference) 
 5.6-6.9 mmol/L 1.02 (0.77, 1.34) 
 
0.96 (0.73, 1.26) 0.95 (0.54, 1.68) 
 
0.87 (0.49, 1.54) 
≥7.0 mmol/L 1.49 (0.96, 2.31) 
 
0.86 (0.54, 1.39) 1.51 (0.65, 3.50) 
 
0.70 (0.29, 1.73) 
Diagnosis of diabetes 
      
 <7.2 mmol/L 2.79 (1.54, 5.04) 
 
2.09 (1.15, 3.80) 3.40 (1.15, 10.07) 
 
2.32 (0.77, 6.94) 
≥7.2 mmol/L 5.65 (4.11, 7.76)   1.75 (1.12, 2.74) 12.25 (7.08, 21.19)   2.74 (1.31, 5.71) 
HbA1c 
No diagnosis of diabetes       
HbA1c <5.7% 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 
 
HbA1c 5.7-6.4% 1.47 (1.09, 1.97) 1.43 (1.06, 1.92) 
 
1.58 (0.86, 2.91) 1.54 (0.84, 2.83) 
 
HbA1c ≥6.5% 3.25 (2.14, 4.93) 2.66 (1.71, 4.16) 
 
4.10 (1.96, 8.56) 3.14 (1.46, 6.77) 
 
Diagnosis of diabetes 
      
HbA1c <7.0% 2.33 (1.38, 3.94) 2.09 (1.23, 3.55) 
 
4.14 (1.70, 10.10) 3.55 (1.45, 8.73) 
 
HbA1c ≥7.0% 8.74 (6.50, 11.75) 5.73 (3.74, 8.79) 
 




Model 1 was adjusted for age (years), race (black, white), sex (male, female), education level, body mass index, total cholesterol, high-density lipoprotein 
cholesterol, drinking status (current, former, never), smoking status (current, former, never), systolic blood pressure, blood pressure–lowering medication use, 
cholesterol–lowering medication use, estimated glomerular filtration rate, history of coronary artery disease and stroke. Model 2a was adjusted for all variables in 




Table 3. Adjusted HRs (95% CIs) for peripheral artery disease and critical limb ischemia by categories of fructosamine, glycated albumin, and 1,5-
AG (N = 10,310) 
 
 
Peripheral artery disease  
n=365 
  
Critical limb ischemia 
n=126 
 
Model 1 Model 2a Model 2b 
 
Model 1 Model 2a Model 2b 
Fructosamine 
       
No diagnosis of diabetes 
       
<77th Percentile 
(<241.5 μmol/L) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(241.5 - 270.0 μmol/L) 0.72 (0.50, 1.04) 0.69 (0.48, 0.99) 0.68 (0.47, 0.97)  0.44 (0.19, 1.06) 0.43 (0.18, 1.02) 0.41 (0.17, 0.97) 
≥96th Percentile 
(≥270.1 μmol/L) 1.73 (1.09, 2.73) 1.21 (0.74, 1.98) 0.93 (0.56, 1.54)  2.58 (1.25, 5.32) 1.76 (0.82, 3.77) 1.14 (0.51, 2.53) 
Diagnosis of diabetes 
       
<32nd Percentile 
(<275.3 μmol/L) 2.86 (1.85, 4.41) 2.42 (1.56, 3.76) 2.09 (1.34, 3.25)  5.50 (2.79, 10.83) 4.60 (2.32, 9.13) 3.64 (1.82, 7.28) 
≥32nd Percentile 
(≥275.3 μmol/L) 5.72 (4.30, 7.60) 2.73 (1.77, 4.21) 1.62 (1.03, 2.54)  12.30 (7.82, 19.37) 5.52 (2.94, 10.37) 2.60 (1.31, 5.15) 
Glycated albumin 
       
No diagnosis of diabetes 
       
<77th Percentile 
(<13.6%) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(13.6 - 15.5%) 
1.09 (0.77, 1.55) 1.06 (0.75, 1.50) 1.01 (0.71, 1.43) 
 
1.10 (0.54, 2.24) 1.08 (0.53, 2.20) 1.01 (0.50, 2.07) 
≥96th Percentile 
(≥15.6%) 
2.45 (1.58, 3.79) 1.83 (1.14, 2.95) 1.34 (0.82, 2.18) 
 
4.69 (2.38, 9.26) 3.50 (1.71, 7.20) 2.26 (1.06, 4.82) 
Diagnosis of diabetes 




2.51 (1.57, 4.02) 2.22 (1.38, 3.57) 1.95 (1.21, 3.14) 
 
4.75 (2.19, 10.33) 4.21 (1.93, 9.20) 3.51 (1.60, 7.70) 
≥32nd Percentile 
(≥16.4%) 
6.90 (5.21, 9.13) 3.98 (2.60, 6.08) 2.30 (1.47, 3.59) 
 
17.32 (10.89, 27.55) 9.78 (5.23, 18.27) 4.74 (2.41, 9.32) 
1,5-AG 
       
No diagnosis of diabetes 
       
>23rd Percentile 
(>14.6 ug/ml) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
5th-23rd Percentile 
(7.9 - 14.6 ug/ml) 
0.90 (0.64, 1.27) 0.89 (0.63, 1.26) 0.88 (0.63, 1.24) 
 
0.69 (0.32, 1.47) 0.69 (0.32, 1.47) 0.68 (0.32, 1.45) 
 ≤4th Percentile 
(≤7.8 ug/ml) 
1.90 (1.18, 3.05) 1.50 (0.91, 2.47) 1.17 (0.70, 1.96) 
 
2.81 (1.26, 6.27) 2.09 (0.90, 4.87) 1.35 (0.56, 3.28) 
Diagnosis of diabetes 
       
>68th Percentile 
(>9.7 ug/ml) 
1.95 (1.18, 3.23) 1.68 (1.01, 2.81) 1.50 (0.90, 2.50) 
 
3.18 (1.41, 7.14) 2.72 (1.20, 6.16) 2.26 (0.99, 5.13) 
≤68th Percentile 
(≤9.7 ug/ml) 
6.74 (5.13, 8.86) 3.99 (2.66, 5.98) 2.41 (1.57, 3.71) 
 
14.73 (9.54, 22.76) 8.27 (4.54, 15.06) 3.97 (2.05, 7.69) 
Models are the same as Table 2. 
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Figure 1. Adjusted incidence rates of peripheral artery disease by (A) fasting blood glucose, (B) 
HbA1c, (C) fructosamine, (D) glycated albumin, and (E) 1,5-AG.  
The graph shows incidence rate per 1,000 person-years and 95% CIs (shaded area) of PAD with spline terms 
of A1c (knots at 5.7, 6.5, and 7%), fasting glucose (knots at 5.0, 5.6, and 7mmol/l), fructosamine, glycated 
albumin, and 1,5-AG (knots at the 5th, 35th, 65th, and 95th percentiles) adjusted for age, race, and sex; 
trimmed at 1% and 99%. Frequency histograms were shown for persons without diabetes (gray bars) and for 











Web Table 1. Adjusted HRs (95% CIs) for peripheral artery disease and critical limb ischemia by categories of fructosamine, glycated albumin, and 1,5-AG 




Peripheral artery disease  
n=365 
  
Critical limb ischemia 
n=126 
 
Model 1 Model 2a Model 2b 
 
Model 1 Model 2a Model 2b 
Fructosamine 
 
      
No diagnosis of diabetes 
       
<77th Percentile 
(<241.5 μmol/L) 
1.39 (0.97, 2.00) 1.45 (1.01, 2.09) 1.48 (1.03, 2.13) 
 
2.26 (0.95, 5.39) 2.35 (0.99, 5.61) 2.46 (1.03, 5.86) 
77th-95th Percentile 
(241.5 - 270.0 μmol/L) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
≥96th Percentile 
(≥270.1 μmol/L) 
2.40 (1.40, 4.09) 1.75 (1.00, 3.07) 1.37 (0.77, 2.43) 
 
5.82 (2.09, 16.22) 4.13 (1.44, 11.82) 2.80 (0.96, 8.21) 
Diagnosis of diabetes 
       
<32nd Percentile 
(<275.3 μmol/L) 
3.97 (2.34, 6.73) 3.51 (2.06, 5.97) 3.09 (1.81, 5.25) 
 
12.41 (4.49, 34.28) 10.82 (3.90, 29.99) 8.94 (3.22, 24.82) 
≥32nd Percentile 
(≥275.3 μmol/L) 
7.94 (5.32, 11.84) 3.96 (2.39, 6.55) 2.39 (1.42, 4.01) 
 
27.77 (11.73, 65.75) 12.98 (4.98, 33.81) 6.39 (2.38, 17.13) 
Glycated albumin 
       
No diagnosis of diabetes 
       
<77th Percentile 
(<13.6%) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(13.6 - 15.5%) 
1.09 (0.77, 1.55) 1.06 (0.75, 1.50) 1.01 (0.71, 1.43) 
 
1.10 (0.54, 2.24) 1.08 (0.53, 2.20) 1.01 (0.50, 2.07) 
≥96th Percentile 
(≥15.6%) 
2.45 (1.58, 3.79) 1.83 (1.14, 2.95) 1.34 (0.82, 2.18) 
 
4.69 (2.38, 9.26) 3.50 (1.71, 7.20) 2.26 (1.06, 4.82) 
Diagnosis of diabetes 
       
<32nd Percentile 
(<16.4%) 
2.51 (1.57, 4.02) 2.22 (1.38, 3.57) 1.95 (1.21, 3.14) 
 
4.75 (2.19, 10.33) 4.21 (1.93, 9.20) 3.51 (1.60, 7.70) 
≥32nd Percentile 
(≥16.4%) 
6.90 (5.21, 9.13) 3.98 (2.60, 6.08) 2.30 (1.47, 3.59)   17.32 (10.89, 27.55) 9.78 (5.23, 18.27) 4.74 (2.41, 9.32) 
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1,5-AG 
       
No diagnosis of diabetes 
       
>23rd Percentile 
(>14.6 ug/ml) 
1.11 (0.79, 1.56) 1.12 (0.80, 1.58) 1.13 (0.80, 1.59) 
 
1.46 (0.68, 3.13) 1.46 (0.68, 3.12) 1.47 (0.69, 3.15) 
5th-23rd Percentile 
(7.9 - 14.6 ug/ml) 
1 (reference) 1 (reference) 1 (reference) 
 
1 (reference) 1 (reference) 1 (reference) 
 ≤4th Percentile 
(≤7.8 ug/ml) 
2.11 (1.22, 3.64) 1.68 (0.95, 2.96) 1.32 (0.74, 2.36) 
 
4.10 (1.48, 11.36) 3.04 (1.06, 8.71) 1.99 (0.67, 5.88) 
Diagnosis of diabetes 
       
>68th Percentile 
(>9.7 ug/ml) 
2.16 (1.22, 3.83) 1.89 (1.06, 3.37) 1.69 (0.95, 3.02) 
 
4.63 (1.66, 12.93) 3.96 (1.41, 11.11) 3.32 (1.18, 9.33) 
≤68th Percentile 
(≤9.7 ug/ml) 
7.47 (5.08, 10.98) 4.47 (2.76, 7.25) 2.73 (1.65, 4.50) 
 
21.49 (10.03, 46.06) 12.03 (5.06, 28.59) 5.84 (2.37, 14.39) 






Web Table 2. Adjusted HRs (95% CIs) for peripheral artery disease without critical limb ischemia 
by categories of fasting glucose and HbA1c (N = 10,310) 
 
  
PAD without CLI 
n=239 
 
Model 1 Model 2a Model 2b 
Fasting glucose 
   
No diagnosis of diabetes 
  
 <5.6 mmol/L 1 (reference) 
 
1 (reference) 
 5.6-6.9 mmol/L 1.05 (0.77, 1.43) 
 
1.00 (0.73, 1.37) 
≥7.0 mmol/L 1.55 (0.93, 2.60) 
 
1.08 (0.61, 1.89) 
Diagnosis of diabetes 
  
 <7.2 mmol/L 2.60 (1.28, 5.28) 
 
2.13 (1.04, 4.37) 
 ≥7.2 mmol/L 3.08 (2.00, 4.77)   1.34 (0.73, 2.48) 
HbA1c 
No diagnosis of diabetes   
HbA1c <5.7% 1 (reference) 1 (reference) 
 
HbA1c 5.7-6.4% 1.49 (1.06, 2.09) 1.47 (1.05, 2.07) 
 
HbA1c ≥6.5% 3.19 (1.91, 5.34) 3.03 (1.73, 5.30) 
 
Diagnosis of diabetes 
  
HbA1c <7.0% 1.85 (0.96, 3.58) 1.80 (0.92, 3.51) 
 
HbA1c ≥7.0% 4.72 (3.12, 7.16) 4.23 (2.28, 7.84) 
 



















Web Table 3. Adjusted HRs (95% CIs) for peripheral artery disease without critical limb ischemia 
by categories of fructosamine, glycated albumin, and 1,5-AG (N = 10,310) (lowest level as 
reference [highest for 1,5-AG]) 
  
PAD without CLI 
n=239 
 
Model 1 Model 2a Model 2b 
Fructosamine 
   
No diagnosis of diabetes 
   
<77th Percentile 
(<241.5 μmol/L) 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(241.5 - 270.0 μmol/L) 
0.86 (0.58, 1.29) 0.83 (0.56, 1.25) 0.82 (0.55, 1.23) 
≥96th Percentile 
(≥270.1 μmol/L) 
1.44 (0.79, 2.64) 1.12 (0.58, 2.16) 0.95 (0.49, 1.84) 
Diagnosis of diabetes 
   
<32nd Percentile 
(<275.3 μmol/L) 
2.03 (1.14, 3.62) 1.79 (0.99, 3.23) 1.62 (0.90, 2.92) 
≥32nd Percentile 
(≥275.3 μmol/L) 
3.20 (2.12, 4.83) 1.87 (0.99, 3.55) 1.28 (0.67, 2.43) 
Glycated albumin 
   
No diagnosis of diabetes 
   
<77th Percentile 
(<13.6%) 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(13.6 - 15.5%) 
1.16 (0.78, 1.74) 1.14 (0.76, 1.70) 1.09 (0.73, 1.64) 
≥96th Percentile 
(≥15.6%) 
1.78 (0.98, 3.24) 1.45 (0.75, 2.80) 1.15 (0.59, 2.25) 
Diagnosis of diabetes 
   
<32nd Percentile 
(<16.4%) 
1.91 (1.05, 3.47) 1.74 (0.95, 3.20) 1.58 (0.86, 2.91) 
≥32nd Percentile 
(≥16.4%) 
3.63 (2.42, 5.45) 2.45 (1.30, 4.60) 1.59 (0.83, 3.05) 
1,5-AG 
   
No diagnosis of diabetes 
   
>23rd Percentile 
(>14.6 ug/ml) 
1 (reference) 1 (reference) 1 (reference) 
5th-23rd Percentile 
(7.9 - 14.6 ug/ml) 
1.00 (0.68, 1.47) 0.99 (0.68, 1.45) 0.98 (0.67, 1.44) 
 ≤4th Percentile 
(≤7.8 ug/ml) 
1.62 (0.89, 2.92) 1.41 (0.76, 2.64) 1.21 (0.64, 2.29) 
Diagnosis of diabetes 
   
>68th Percentile 
(>9.7 ug/ml) 
1.54 (0.80, 2.95) 1.40 (0.72, 2.72) 1.28 (0.66, 2.49) 
≤68th Percentile 
(≤9.7 ug/ml) 
3.72 (2.51, 5.53) 2.67 (1.48, 4.81) 1.85 (1.00, 3.39) 










Web Table 4. Adjusted HRs (95% CIs) for peripheral artery disease without critical limb ischemia 
by categories of fructosamine, glycated albumin, and 1,5-AG (N = 10,310) (lowest risk group as 
reference) 
  
PAD without CLI 
n=239 
 
Model 1 Model 2a Model 2b 
Fructosamine 
   
No diagnosis of diabetes 
   
<77th Percentile 
(<241.5 μmol/L) 
1.16 (0.78, 1.73) 1.20 (0.80, 1.79) 1.22 (0.81, 1.82) 
77th-95th Percentile 
(241.5 - 270.0 μmol/L) 
1 (reference) 1 (reference) 1 (reference) 
≥96th Percentile 
(≥270.1 μmol/L) 
1.67 (0.85, 3.28) 1.35 (0.66, 2.74) 1.16 (0.56, 2.37) 
Diagnosis of diabetes 
   
<32nd Percentile 
(<275.3 μmol/L) 
2.35 (1.21, 4.57) 2.15 (1.10, 4.21) 1.97 (1.00, 3.85) 
≥32nd Percentile 
(≥275.3 μmol/L) 
3.70 (2.22, 6.17) 2.25 (1.13, 4.46) 1.55 (0.78, 3.10) 
Glycated albumin 
   
No diagnosis of diabetes 
   
<77th Percentile 
(<13.6%) 
1 (reference) 1 (reference) 1 (reference) 
77th-95th Percentile 
(13.6 - 15.5%) 
1.16 (0.78, 1.74) 1.14 (0.76, 1.70) 1.09 (0.73, 1.64) 
≥96th Percentile 
(≥15.6%) 
1.78 (0.98, 3.24) 1.45 (0.75, 2.80) 1.15 (0.59, 2.25) 
Diagnosis of diabetes 
   
<32nd Percentile 
(<16.4%) 
1.91 (1.05, 3.47) 1.74 (0.95, 3.20) 1.58 (0.86, 2.91) 
≥32nd Percentile 
(≥16.4%) 
3.63 (2.42, 5.45) 2.45 (1.30, 4.60) 1.59 (0.83, 3.05) 
1,5-AG 
   
No diagnosis of diabetes 
   
>23rd Percentile 
(>14.6 ug/ml) 
1.00 (0.68, 1.46) 1.01 (0.69, 1.48) 1.02 (0.69, 1.49) 
5th-23rd Percentile 
(7.9 - 14.6 ug/ml) 
1 (reference) 1 (reference) 1 (reference) 
 ≤4th Percentile 
(≤7.8 ug/ml) 
1.61 (0.83, 3.14) 1.42 (0.71, 2.84) 1.23 (0.61, 2.49) 
Diagnosis of diabetes 
   
>68th Percentile 
(>9.7 ug/ml) 
1.53 (0.75, 3.15) 1.41 (0.68, 2.92) 1.30 (0.63, 2.70) 
≤68th Percentile 
(≤9.7 ug/ml) 
3.72 (2.26, 6.11) 2.69 (1.40, 5.17) 1.88 (0.96, 3.67) 
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